D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, vol.100, pp.57-70, 2000.

L. H. Hartwell and T. A. Weinert, Checkpoints: controls that ensure the order of cell cycle events, Science, vol.246, pp.629-663, 1989.

C. Giacinti and A. Giordano, RB and cell cycle progression, Oncogene, vol.25, pp.5220-5227, 2006.

R. A. Weinberg, The retinoblastoma protein and cell cycle control, Cell, vol.81, pp.323-353, 1995.

E. W. Lam, L. Thangue, and N. B. , DP and E2F proteins: coordinating transcription with cell cycle progression, Curr Opin Cell Biol, vol.6, pp.859-66, 1994.

J. W. Harbour, R. X. Luo, D. Santi, A. Postigo, A. A. Dean et al., Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G 1, Cell, vol.98, pp.859-69, 1999.

C. J. Sherr and J. M. Roberts, CDK inhibitors: positive and negative regulators of G 1 -phase progression, Genes Dev, vol.13, pp.1501-1513, 1999.

M. Malumbres and M. Barbacid, Mammalian cyclin-dependent kinases, Trends Biochem Sci, vol.30, pp.630-671, 2005.

A. R. Barr and F. Gergely, Aurora-A: the maker and breaker of spindle poles, J Cell Sci, vol.120, pp.2987-96, 2007.

V. Archambault and D. M. Glover, Polo-like kinases: conservation and divergence in their functions and regulation, Nat Rev Mol Cell Biol, vol.10, pp.265-75, 2009.

T. Marumoto, D. Zhang, and H. Saya, Aurora-A-a guardian of poles, Nat Rev Cancer, vol.5, pp.42-50, 2005.

G. Vader, R. H. Medema, and S. M. Lens, The chromosomal passenger complex: guiding Aurora-B through mitosis, J Cell Biol, vol.173, pp.833-840, 2006.

C. J. Tang, C. Y. Lin, and T. K. Tang, Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis, Dev Biol, vol.290, pp.398-410, 2006.

K. Sasai, H. Katayama, D. L. Stenoien, S. Fujii, R. Honda et al., Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells, Cell Motil Cytoskeleton, vol.59, pp.249-63, 2004.

K. Strebhardt and A. Ullrich, Targeting polo-like kinase 1 for cancer therapy, Nat Rev Cancer, vol.6, pp.321-351, 2006.

F. A. Barr, H. H. Sillje, and E. A. Nigg, Polo-like kinases and the orchestration of cell division, Nat Rev Mol Cell Biol, vol.5, pp.429-469, 2004.

J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort et al., DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis, Nature, vol.434, pp.864-70, 2005.

V. G. Gorgoulis, L. V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas et al., Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions, Nature, vol.434, pp.907-920, 2005.

Y. Shiloh, ATM and related protein kinases: safeguarding genome integrity, Nat Rev Cancer, vol.3, pp.155-68, 2003.

J. Yokota, N. Mori, T. Akiyama, Y. Shimosato, T. Sugimura et al., Multiple genetic alterations in smallcell lung carcinoma, Princess Takamatsu Symp, vol.20, pp.43-51, 1989.

J. W. Harbour, S. L. Lai, J. Whang-peng, A. F. Gazdar, J. D. Minna et al., Abnormalities in structure and expression of the human retinoblastoma gene in SCLC, Science, vol.241, pp.353-360, 1988.

V. Gouyer, S. Gazzeri, I. Bolon, C. Drevet, C. Brambilla et al., Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors, Am J Respir Cell Mol Biol, vol.18, pp.188-96, 1998.

V. Gouyer, S. Gazzeri, E. Brambilla, I. Bolon, D. Moro et al., Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas, Int J Cancer, vol.58, pp.818-842, 1994.

Y. Haga, K. Hiroshima, A. Iyoda, K. Shibuya, F. Shimamura et al., Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer, Ann Thorac Surg, vol.75, pp.1727-1759, 2003.

P. T. Reissmann, H. Koga, R. Takahashi, R. A. Figlin, E. C. Holmes et al., Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group, Oncogene, vol.8, pp.1913-1922, 1993.

S. Ishihara, K. Minato, H. Hoshino, R. Saito, F. Hara et al., The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens, Lung Cancer, vol.26, pp.187-94, 1999.

Y. Yatabe, A. Masuda, T. Koshikawa, S. Nakamura, T. Kuroishi et al., p27 KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas, Cancer Res, vol.58, pp.1042-1049, 1998.

A. Masuda, H. Osada, Y. Yatabe, K. Kozaki, Y. Tatematsu et al., Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments, Am J Pathol, vol.158, pp.87-96, 2001.

V. Esposito, A. Baldi, A. De-luca, A. M. Groger, M. Loda et al., Prognostic role of the cyclindependent kinase inhibitor p27 in non-small cell lung cancer, Cancer Res, vol.57, pp.3381-3386, 1997.

S. Yokoi, K. Yasui, F. Saito-ohara, K. Koshikawa, T. Iizasa et al., A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers, Am J Pathol, vol.161, pp.207-223, 2002.

C. Salon, G. Merdzhanova, C. Brambilla, E. Brambilla, S. Gazzeri et al., E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors, Oncogene, vol.26, pp.6927-6963, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00173067

I. S. Pateras, K. Apostolopoulou, M. Koutsami, K. Evangelou, P. Tsantoulis et al., Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer, Int J Cancer, vol.119, pp.2546-56, 2006.

T. Kobatake, M. Yano, S. Toyooka, K. Tsukuda, H. Dote et al., Aberrant methylation of p57 KIP2 gene in lung and breast cancers and malignant mesotheliomas, Oncol Rep, vol.12, pp.1087-92, 2004.

H. Z. Chen, S. Y. Tsai, and G. Leone, Emerging roles of E2Fs in cancer: an exit from cell cycle control, Nat Rev Cancer, vol.9, pp.785-97, 2009.

B. Eymin, S. Gazzeri, C. Brambilla, and E. Brambilla, Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma, Oncogene, vol.20, pp.1678-87, 2001.

G. Tonon, K. K. Wong, G. Maulik, C. Brennan, B. Feng et al., High-resolution genomic profiles of human lung cancer, Proc Natl Acad Sci, vol.102, pp.9625-9655, 2005.

V. G. Gorgoulis, P. Zacharatos, G. Mariatos, A. Kotsinas, M. Bouda et al., Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas, J Pathol, vol.198, pp.142-56, 2002.

C. L. Huang, D. Liu, J. Nakano, H. Yokomise, M. Ueno et al., E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer, Clin Cancer Res, vol.13, pp.6938-6984, 2007.

P. Karakaidos, S. Taraviras, L. V. Vassiliou, P. Zacharatos, N. G. Kastrinakis et al., Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 transcriptional control over hCdt1, Am J Pathol, vol.165, pp.1351-65, 2004.

M. A. Imai, Y. Oda, M. Oda, I. Nakanishi, and E. Kawahara, Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma, J Cancer Res Clin Oncol, vol.130, pp.320-326, 2004.

T. Ried, I. Petersen, H. Holtgreve-grez, M. R. Speicher, E. Schrock et al., Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization, Cancer Res, vol.54, pp.1801-1807, 1994.

J. P. Packenham, J. A. Taylor, C. M. White, C. H. Anna, J. C. Barrett et al., Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers, Clin Cancer Res, vol.1, pp.687-90, 1995.

S. Xiao, D. Li, J. M. Corson, J. Vijg, and J. A. Fletcher, Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma, Cancer Res, vol.55, pp.2968-71, 1995.

K. Hamada, T. Kohno, M. Kawanishi, S. Ohwada, and J. Yokota, Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma, Genes Chromosomes Cancer, vol.22, pp.232-272, 1998.

J. G. Herman, J. J. Merlo, A. Baylin, and S. B. , Hypermethylation-associated inactivation indicates a tumor suppressor role for p15 INK4B, Cancer Res, vol.56, pp.722-729, 1996.

O. Furonaka, Y. Takeshima, H. Awaya, H. Ishida, N. Kohno et al., Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma, Pathol Int, vol.54, pp.549-55, 2004.

A. Okamoto, S. P. Hussain, K. Hagiwara, E. A. Spillare, M. R. Rusin et al., Mutations in the p16 INK4 /MTS1/CDKN2, p15 INK4B /MTS2 and p18 genes in primary and metastatic lung cancer, Cancer Res, vol.55, pp.1448-51, 1995.

M. R. Rusin, A. Okamoto, M. Chorazy, K. Czyzewski, J. Harasim et al., Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers, Int J Cancer, vol.65, pp.734-743, 1996.

L. Chaussade, B. Eymin, E. Brambilla, and S. Gazzeri, Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status, Oncogene, vol.20, pp.6587-96, 2001.

N. Kawamata, C. W. Miller, and H. P. Koeffler, Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in nonsmall cell lung cancers, Mol Carcinog, vol.14, pp.263-271, 1995.

X. H. Pei, F. Bai, M. D. Smith, and Y. Xiong, p18 Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers, Cancer Res, vol.67, pp.3162-70, 2007.

T. Komiya, Y. Hosono, T. Hirashima, N. Masuda, T. Yasumitsu et al., p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung, Clin Cancer Res, vol.3, pp.1831-1836, 1997.

T. Shoji, F. Tanaka, T. Takata, K. Yanagihara, Y. Otake et al., Clinical significance of p21 expression in non-small-cell lung cancer, J Clin Oncol, vol.20, pp.3865-71, 2002.

V. Esposito, A. Baldi, G. Tonini, B. Vincenzi, M. Santini et al., Analysis of cell cycle regulator proteins in non-small cell lung cancer, J Clin Pathol, vol.57, pp.58-63, 2004.

C. Catzavelos, M. S. Tsao, G. Deboer, N. Bhattacharya, F. A. Shepherd et al., Reduced expression of the cell cycle inhibitor p27 Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras, Cancer Res, vol.59, pp.684-692, 1999.

H. Hayashi, N. Ogawa, N. Ishiwa, T. Yazawa, Y. Inayama et al., High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients, Lung Cancer, vol.34, pp.59-65, 2001.

S. Takahashi, Y. Kamata, W. Tamo, M. Koyanagi, R. Hatanaka et al., Relationship between postoperative recurrence and expression of cyclin E, p27 and Ki-67 in non-small cell lung cancer without lymph node metastases, Int J Clin Oncol, vol.7, pp.349-55, 2002.

S. Tsukamoto, K. Sugio, T. Sakada, C. Ushijima, K. Yamazaki et al., Reduced expression of cell cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer, Lung Cancer, vol.34, pp.83-90, 2001.

T. A. D'amico, M. Massey, J. E. Herndon, M. B. Moore, and D. H. Harpole, A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers, J Thorac Cardiovasc Surg, vol.117, pp.736-779, 1999.

P. P. Claudio, C. M. Howard, C. Pacilio, C. Cinti, G. Romano et al., Mutations in the retinoblastomarelated gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer, Cancer Res, vol.60, pp.372-82, 2000.

A. Baldi, V. Esposito, D. Luca, A. Fu, Y. Meoli et al., Differential expression of Rb2/ p130 and p107 in normal human tissues and in primary lung cancer, Clin Cancer Res, vol.3, pp.1691-1698, 1997.

A. Baldi, V. Esposito, D. Luca, A. Howard, C. M. Mazzarella et al., Differential expression of the retinoblastoma gene family members pRb/p105, p107 and pRb2/p130 in lung cancer, Clin Cancer Res, vol.2, pp.1239-1284, 1996.

K. Helin, K. Holm, A. Niebuhr, H. Eiberg, N. Tommerup et al., Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma, Proc Natl Acad Sci, vol.94, pp.6933-6941, 1997.

G. I. Shapiro, C. D. Edwards, L. Kobzik, J. Godleski, W. Richards et al., Reciprocal Rb inactivation and p16 INK4 expression in primary lung cancers and cell lines, Cancer Res, vol.55, pp.505-514, 1995.

S. Gazzeri, V. Gouyer, C. Vour'ch, C. Brambilla, and E. Brambilla, Mechanisms of p16 INK4A inactivation in non smallcell lung cancers, Oncogene, vol.16, pp.497-504, 1998.

J. S. Wiest, W. A. Franklin, J. T. Otstot, K. Forbey, M. Varella-garcia et al., Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene, Cancer Res, vol.57, pp.1-6, 1997.

S. A. Belinsky, K. J. Nikula, W. A. Palmisano, R. Michels, G. Saccomanno et al., Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proc Natl Acad Sci, vol.95, pp.11891-11897, 1998.

S. Singhal, A. Vachani, D. Antin-ozerkis, L. R. Kaiser, and S. M. Albelda, Prognostic implications of cell cycle, apoptosis and angiogenesis biomarkers in non-small cell lung cancer: a review, Clin Cancer Res, vol.11, pp.3974-86, 2005.

A. Marchetti, C. Doglioni, M. Barbareschi, F. Buttitta, S. Pellegrini et al., Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer, Int J Cancer, vol.75, pp.187-92, 1998.

D. C. Betticher, J. Heighway, P. S. Hasleton, H. J. Altermatt, W. D. Ryder et al., Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer, Br J Cancer, vol.73, pp.294-300, 1996.

O. Gautschi, D. Ratschiller, M. Gugger, D. C. Betticher, and J. Heighway, Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation, Lung Cancer, vol.55, pp.1-14, 2007.

E. Brambilla, S. Gazzeri, D. Moro, S. Lantuejoul, S. Veyrenc et al., Alterations of Rb pathway (Rb-p16 INK4 -cyclin D1) in preinvasive bronchial lesions, Clin Cancer Res, vol.5, pp.243-50, 1999.

M. Jeanmart, S. Lantuejoul, F. Fievet, D. Moro, N. Sturm et al., Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer, Clin Cancer Res, vol.9, pp.2195-203, 2003.

M. Jin, S. Inoue, T. Umemura, J. Moriya, M. Arakawa et al., Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II, Lung Cancer, vol.34, pp.207-225, 2001.

H. Wikman, P. Nymark, A. Vayrynen, S. Jarmalaite, A. Kallioniemi et al., CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer, Genes Chromosomes Cancer, vol.42, pp.193-202, 2005.

D. S. Kim, M. J. Kim, J. Y. Lee, S. M. Lee, J. E. Choi et al., Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features, Lung Cancer, vol.65, pp.247-50, 2009.

N. Haruki, H. Saito, Y. Tatematsu, H. Konishi, T. Harano et al., Histological type-selective, tumorpredominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer, Cancer Res, vol.60, pp.4689-92, 2000.

A. Gemma, M. Seike, Y. Seike, K. Uematsu, S. Hibino et al., Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer, Genes Chromosomes Cancer, vol.29, pp.213-221, 2000.

S. Nomoto, N. Haruki, T. Takahashi, A. Masuda, T. Koshikawa et al., Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers, Oncogene, vol.18, pp.7180-7183, 1999.

L. S. Michel, V. Liberal, A. Chatterjee, R. Kirchwegger, B. Pasche et al., MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells, Nature, vol.409, pp.355-364, 2001.

J. R. Babu, K. B. Jeganathan, D. J. Baker, X. Wu, N. Kang-decker et al., Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation, J Cell Biol, vol.160, pp.341-53, 2003.

S. Lapenna and A. Giordano, Cell cycle kinases as therapeutic targets for cancer, Nat Rev Drug Discov, vol.8, pp.547-66, 2009.

S. L. George, Statistical issues in translational cancer research, Clin Cancer Res, vol.14, pp.5954-5962, 2008.

E. Kodym, R. Kodym, A. E. Reis, A. A. Habib, M. D. Story et al., The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells, Lung Cancer, vol.66, pp.37-47, 2009.

C. Benson, J. White, D. Bono, J. , O. Donnell et al., A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days, Br J Cancer, vol.96, pp.29-37, 2007.

E. A. Harrington, D. Bebbington, J. Moore, R. K. Rasmussen, A. O. Ajose-adeogun et al., VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo, Nat Med, vol.10, pp.262-269, 2004.

I. Hickson, Y. Zhao, C. J. Richardson, S. J. Green, N. M. Martin et al., Identification and characterization of a novel and specific inhibitor of the ataxiatelangiectasia mutated kinase ATM, Cancer Res, vol.64, pp.9152-9161, 2004.

M. D. Rainey, M. E. Charlton, R. V. Stanton, and M. B. Kastan, Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation, Cancer Res, vol.68, pp.7466-74, 2008.

J. Gu, Y. Gong, M. Huang, C. Lu, M. R. Spitz et al., Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians, Carcinogenesis, vol.28, pp.350-355, 2007.

S. L. Smith, N. L. Bowers, D. C. Betticher, O. Gautschi, D. Ratschiller et al., Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability, Br J Cancer, vol.93, pp.719-748, 2005.

J. Heighway, T. Knapp, L. Boyce, S. Brennand, J. K. Field et al., Expression profiling of primary non-small cell lung cancer for target identification, Oncogene, vol.21, pp.7749-63, 2002.

B. Vischioni, J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone, Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients, Mol Cancer Ther, vol.5, pp.2905-2918, 2006.

C. K. Jung, J. H. Jung, G. S. Park, A. Lee, C. S. Kang et al., Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer, Pathol Int, vol.56, pp.503-512, 2006.

Y. Ma, D. Lin, W. Sun, T. Xiao, J. Yuan et al., Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer, Clin Cancer Res, vol.12, pp.1121-1128, 2006.

P. G. Corn, M. K. Summers, F. Fogt, A. K. Virmani, A. F. Gazdar et al., Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer, Carcinogenesis, vol.24, pp.47-51, 2003.

G. Mariatos, J. Bothos, P. Zacharatos, M. K. Summers, D. M. Scolnick et al., Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer, Cancer Res, vol.63, pp.7185-7194, 2003.

L. Ding, G. Getz, D. A. Wheeler, E. R. Mardis, M. D. Mclellan et al., Somatic mutations affect key pathways in lung adenocarcinoma, Nature, vol.455, pp.1069-75, 2008.

S. Landi, F. Gemignani, F. Canzian, V. Gaborieau, R. Barale et al., DNA repair and cell cycle control genes and the risk of young-onset lung cancer, Cancer Res, vol.66, pp.11062-11071, 2006.

B. Eymin, P. Claverie, C. Salon, C. Leduc, E. Col et al., p14 ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress, Mol Cell Biol, vol.26, pp.4339-50, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00175818

C. M. Raynaud, O. Mercier, F. Commo, P. Dartevelle, C. Gomez-roca et al., Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases, Lung Cancer, vol.65, pp.144-153, 2009.

R. A. Ditullio, T. A. Mochan, M. Venere, J. Bartkova, M. Sehested et al., 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer, Nat Cell Biol, vol.4, pp.998-1002, 2002.

P. G. Nuciforo, C. Luise, M. Capra, and G. Pelosi, Adda di Fagagna F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression, Carcinogenesis, vol.28, pp.2082-2090, 2007.

P. Zhang, J. Wang, W. Gao, B. Z. Yuan, J. Rogers et al., CHK2 kinase expression is downregulated due to promoter methylation in non-small cell lung cancer, Mol Cancer, vol.3, p.14, 2004.

C. H. Spruck, K. A. Won, and S. I. Reed, Deregulated cyclin E induces chromosome instability, Nature, vol.401, pp.297-300, 1999.

T. Mishina, H. Dosaka-akita, F. Hommura, M. Nishi, T. Kojima et al., Cyclin E expression, a potential prognostic marker for non-small cell lung cancers, Clin Cancer Res, vol.6, pp.11-17, 2000.

T. Fukuse, T. Hirata, H. Naiki, S. Hitomi, and H. Wada, Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer, Cancer Res, vol.60, pp.242-246, 2000.

Y. Ma, S. Fiering, C. Black, X. Liu, Z. Yuan et al., Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas, Proc Natl Acad Sci, vol.104, pp.4089-94, 2007.

C. Muller-tidow, R. Metzger, K. Kugler, S. Diederichs, G. Idos et al., Cyclin E is the only cyclindependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer, Cancer Res, vol.61, pp.647-53, 2001.

H. Dosaka-akita, F. Hommura, T. Mishina, S. Ogura, M. Shimizu et al., A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67 and ras p21: different roles of G 1 cyclins in cell proliferation and prognosis, Cancer Res, vol.61, pp.2500-2504, 2001.

M. Kosacka, P. Piesiak, I. Porebska, A. Korzeniewska, T. Dyla et al., Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA, In Vivo, vol.23, pp.519-544, 2009.

W. A. Cooper, M. R. Kohonen-corish, B. Mccaughan, C. Kennedy, R. L. Sutherland et al., Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer, Histopathology, vol.55, pp.28-36, 2009.

Y. Dobashi, M. Shoji, S. X. Jiang, M. Kobayashi, Y. Kawakubo et al., Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas, Am J Pathol, vol.153, pp.963-72, 1998.

M. Volm, R. Koomagi, J. Mattern, and G. Stammler, Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas, Br J Cancer, vol.75, pp.1774-1782, 1997.

T. Yoshida, S. Tanaka, A. Mogi, Y. Shitara, and H. Kuwano, The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer, Ann Oncol, vol.15, pp.252-258, 2004.

M. Arinaga, T. Noguchi, S. Takeno, M. Chujo, T. Miura et al., Clinical implication of cyclin B1 in non-small cell lung cancer, Oncol Rep, vol.10, pp.1381-1387, 2003.

J. C. Soria, S. J. Jang, F. R. Khuri, K. Hassan, D. Liu et al., Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication, Cancer Res, vol.60, pp.4000-4004, 2000.

S. Singhal, K. M. Amin, R. Kruklitis, P. Delong, M. E. Friscia et al., Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling, Cancer Biol Ther, vol.2, pp.291-299, 2003.

G. Wolf, R. Elez, A. Doermer, U. Holtrich, H. Ackermann et al., Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer, Oncogene, vol.14, pp.543-552, 1997.

M. A. Ko, C. O. Rosario, J. W. Hudson, S. Kulkarni, A. Pollett et al., Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis, Nat Genet, vol.37, pp.883-891, 2005.

H. T. Xu, L. Ma, F. J. Qi, Y. Liu, J. H. Yu et al., Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma, Pathol Int, vol.56, pp.375-80, 2006.